ESMO News

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

This updated ESMO CPG provides diagnosis, staging, risk assessment, treatment and follow-up recommendations. It introduces new systemic treatments and innovative strategies, offering physicians practicing thoracic oncology advanced therapeutic options to improve outcomes and personalise care.

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

The Molecular Analysis for Precision Oncology Congress 2025 (MAP) will bring together leading experts to explore the latest advances in cancer research, with a focus on deepening the understanding of disease mechanism and enhancing strategies for prevention and interception

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

With alcohol consumption increasing the risk of developing at least 7 types of cancer, ESMO considers it crucial that robust policy action - at all political levels - is taken to effectively address the impact of alcohol-related harm on human health, thus enhancing cancer prevention

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

At the conclusion of the 2025 High-Level Political Forum (HLPF) on Sustainable Development, UN Member States adopted a Ministerial Declaration reaffirming commitment to universal health coverage (UHC), resilient health systems, and tackling non-communicable diseases (NCDs) like cancer

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00

FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations

noreply@esmo.org — Fri, 29 Aug 2025 08:08:00 +00:00

Evidence for efficacy is based on the results from the Beamion LUNG-1 study

Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide

noreply@esmo.org — Thu, 28 Aug 2025 08:08:00 +00:00

Findings from the ISG/OS-2 and GEIS-33 studies

Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC

noreply@esmo.org — Wed, 27 Aug 2025 07:08:00 +00:00

Findings from the PEACE-3 study

AI and remote monitoring are shaping a new patient journey in oncology

noreply@esmo.org — Tue, 26 Aug 2025 22:08:00 +00:00

Real world experience suggests that the integration of digital tools into cancer care may close current gaps in patient outcomes reporting

In Memory of Håkan Mellstedt: Former ESMO President

noreply@esmo.org — Tue, 26 Aug 2025 12:08:00 +00:00

It is with deep sadness that ESMO has learnt of the passing of Professor Håkan Mellstedt, who died recently at the age of 82

EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel

noreply@esmo.org — Tue, 26 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy

noreply@esmo.org — Mon, 25 Aug 2025 07:08:00 +00:00

Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative Group

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

noreply@esmo.org — Fri, 22 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC

noreply@esmo.org — Thu, 21 Aug 2025 07:08:00 +00:00

Findings from the KEYNOTE-426 study

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC

noreply@esmo.org — Wed, 20 Aug 2025 07:08:00 +00:00

Findings from the KRYSTAL-12 study

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer

noreply@esmo.org — Tue, 19 Aug 2025 07:08:00 +00:00

Findings from the ASTER 70s study

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

noreply@esmo.org — Mon, 18 Aug 2025 07:08:00 +00:00

It is intended for the treatment of patients with relapsed or refractory multiple myeloma

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to Reduce Preventable Cancer Cases Linked to Alcohol Use

noreply@esmo.org — Thu, 14 Aug 2025 09:08:00 +00:00

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Findings from the CT041-ST-01 study

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

noreply@esmo.org — Thu, 14 Aug 2025 07:08:00 +00:00

Evidence for efficacy is based on the results from the inMIND study

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

noreply@esmo.org — Wed, 13 Aug 2025 07:08:00 +00:00

It is intended for the treatment of adults and adolescents with low grade astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation

Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid Cancer

noreply@esmo.org — Tue, 12 Aug 2025 07:08:00 +00:00

Findings from the IoN study

ESMO Recommendations on Cancer Care Reflected in UN ECOSOC Ministerial Declaration on Sustainable Development

noreply@esmo.org — Mon, 11 Aug 2025 07:08:00 +00:00